Benefit of adjuvant chemotherapy in lymph node-negative, T1b and T1c triple-negative breast cancer

Introduction Current guidelines recommendations regarding chemotherapy in small (T1b and T1c), node-negative triple-negative breast cancer (TNBC) differ due to lack of high-quality data. Our study aimed to assess the benefit of adjuvant chemotherapy in patients with T1bN0M0 and T1cN0M0 TNBC. Methods...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research and treatment 2024, Vol.203 (2), p.257-269
Main Authors: Carbajal-Ochoa, Walter, Bravo-Solarte, Daniela C., Bernal, Ana M., Anampa, Jesus D.
Format: Article
Language:English
Subjects:
Breast - pathology
Breast cancer
Breast Neoplasms - pathology
Cancer research
Chemotherapy
Chemotherapy, Adjuvant
Epidemiology
Female
Humans
Lymph nodes
Lymph Nodes - pathology
Medicine
Medicine & Public Health
Neoplasm Staging
Oncology
Statistical analysis
Survival
Triple Negative Breast Neoplasms - pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Current guidelines recommendations regarding chemotherapy in small (T1b and T1c), node-negative triple-negative breast cancer (TNBC) differ due to lack of high-quality data. Our study aimed to assess the benefit of adjuvant chemotherapy in patients with T1bN0M0 and T1cN0M0 TNBC. Methods We obtained data from the Surveillance, Epidemiology, and End Results database for patients with node-negative, T1b/T1c TNBC diagnosed between 2010 and 2020. Logistic regresion models assessed variables associated with chemotherapy administration. We evaluated the effect of chemotherapy on overall survival (OS) and breast cancer specific survival (BCSS) with Kaplan-Meier methods and Cox proportional hazards methods. Results We included 11,510 patients: 3,388 with T1b and 8,122 with T1c TNBC. During a median follow-up of 66 months, 305 patients with T1b and 995 with T1c died. After adjusting for clinicopathological, demographic and treatment factors, adjuvant chemotherapy improved OS in T1b TNBC (HR, 0.52; 95% CI, 0.41–0.68 p 
ISSN:0167-6806
1573-7217
DOI:10.1007/s10549-023-07132-6